Patents by Inventor Timothy Vitalis

Timothy Vitalis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DEPHOSPHORYLATED LYSOSOMAL STORAGE DISEASE PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20210388330
    Abstract: Provided are substantially dephosphorylated forms of lysosomal storage disease (LSD) proteins, including dephosphorylated forms of iduronate-2-sulfatase (IDS, or 12D) and iduronidase (IDU), having increased ability to traverse or penetrate the blood brain barrier (BBB) relative to phosphorylated forms of the protein, and p97 conjugates thereof. Also provided are compositions comprising such dephosphorylated LSD proteins and p97 conjugates, and methods of use thereof, for instance, to treat any one or more lysosomal storage diseases, such as Hunter Syndrome (or MPS Type II).
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Applicant: Bioasis Technologies, Inc.
    Inventors: Timothy Vitalis, Reinhard Gabathuler
  • ANTIBODIES AGAINST P97 AND CONJUGATES THEREOF
    Publication number: 20180009898
    Abstract: Provided are conjugates between (a) an antibody or antigen-binding fragment thereof that binds to p97 (melanotransferrin; MTf) and (b) an agent of interest, and related compositions and methods, for example, to improve pharmacokinetics and/or delivery of the agent of interest across the blood-brain barrier (BBB) and into tissues of the central nervous system (CNS).
    Type: Application
    Filed: July 7, 2016
    Publication date: January 11, 2018
    Inventor: Timothy Vitalis
  • P97 fragments with transfer activity
    Patent number: 9161992
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 20, 2015
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • P97 FRAGMENTS WITH TRANSFER ACTIVITY
    Publication number: 20150056218
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Application
    Filed: March 26, 2014
    Publication date: February 26, 2015
    Applicant: biOasis Technologies, Inc.
    Inventors: Wilfred Jeffries, Mei Mei Tian, Timothy Vitalis
  • P97 fragments with transfer activity
    Patent number: 8722019
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: May 13, 2014
    Assignee: biOasis Technologies, Inc.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis
  • P97 FRAGMENTS WITH TRANSFER ACTIVITY
    Publication number: 20130058873
    Abstract: The present invention is related to fragments of human melanotransferrin (p97). In particular, this invention relates to treatment of diseases through the introduction of the melanotransferrin fragment conjugated to a therapeutic or diagnostic agent to a subject.
    Type: Application
    Filed: August 3, 2012
    Publication date: March 7, 2013
    Applicant: BIOASIS TECHNOLOGIES, INC.
    Inventors: Wilfred Jefferies, Mei Mei Tian, Timothy Vitalis